Jardiance (empagliflozin) is an oral medication that belongs to the sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitor class. It’s primarily used to help control blood sugar in adults with type 2 diabetes, and it’s also shown benefits in reducing heart failure and kidney‑related complications in people with diabetes.
Typical dosing
| Indication |
Starting dose |
Target dose |
How it’s taken |
| Type 2 diabetes |
10 mg once daily |
25 mg once daily (if tolerated) |
Take with or without food |
| Heart failure (HF) |
10 mg once daily |
25 mg once daily |
Same as above |
| Chronic kidney disease (CKD) |
10 mg once daily |
25 mg once daily |
Same as above |
Note: Jardiance is available only in 10 mg and 25 mg tablets. There is no 12.5 mg formulation. If you or a clinician are seeing a 12.5 mg dose, it might be a typo or a misunderstanding of the dosage schedule (e.g., 10 mg + 5 mg in a split‑dose). Always follow the exact prescription.
How it works
- Mechanism: Empagliflozin blocks SGLT‑2 receptors in the proximal tubule of the kidneys, preventing re‑absorption of glucose back into the bloodstream. The excess glucose is excreted in the urine, lowering blood sugar.
- Additional benefits: The drug also reduces blood pressure, promotes modest weight loss, and has been shown to improve outcomes in heart failure and CKD independent of glucose control.
Common side effects
| Symptom |
Frequency |
Typical management |
| Genital yeast infections (vaginal/penile) |
Mild to moderate |
Topical antifungals; hygiene |
| Urinary tract infections |
Mild |
Treat with antibiotics if needed |
| Thirst, dehydration |
Mild |
Drink fluids; monitor electrolytes |
| Hypoglycemia (rare with SGLT‑2 alone, more common when combined with insulin or sulfonylureas) |
Rare |
Monitor glucose, adjust other meds |
| Low blood pressure (orthostatic hypotension) |
Mild |
Sit/stand slowly, adjust dose |
| Ketoacidosis (rare but serious) |
Rare |
Watch for nausea, vomiting, abdominal pain, confusion; seek urgent care if suspected |
Contraindications & cautions
- Renal impairment: Jardiance is not recommended if eGFR < 45 mL/min/1.73 m². Dose adjustment isn’t necessary for mild‑moderate CKD, but the drug is generally avoided in severe CKD or dialysis.
- Pregnancy & breastfeeding: Not recommended. Animal studies suggest potential harm to the fetus.
- Diabetic ketoacidosis history: Use with caution; monitor ketones.
- Concurrent use with other SGLT‑2 inhibitors: Avoid overlap.
Drug interactions
| Interaction |
Impact |
Recommendation |
| Diuretics (especially thiazides) |
↑ risk of dehydration & hypotension |
Monitor BP & hydration |
| Insulin or sulfonylureas |
↑ hypoglycemia risk |
Reduce dose or add monitoring |
| ACE inhibitors/ARBs |
Possible additive effect on kidney function |
Monitor eGFR |
| Antacids with aluminum or magnesium |
↓ absorption |
Take at least 2 h apart |
What to watch for
- Signs of dehydration: Dry mouth, dizziness, low BP.
- Unusual thirst or weight loss: May be a sign of ketoacidosis.
- Pain or swelling in the lower limbs: Could signal an infection or venous thromboembolism.
- Symptoms of low blood sugar: Shakiness, sweating, confusion—especially if on insulin or sulfonylureas.
If you notice any of these, contact your healthcare provider promptly.
Bottom line
Jardiance is a well‑studied drug that lowers blood sugar by making your kidneys excrete more glucose. While there is no 12.5 mg tablet, the standard doses are 10 mg or 25 mg once daily. The medication offers cardiovascular and renal benefits in addition to glucose control, but you should be aware of its side‑effect profile and the need for careful monitoring—especially if you have kidney problems or are on other glucose‑lowering drugs.
If you have a specific question about your dose, side‑effects, or how Jardiance fits into your overall treatment plan, let me know—I’m happy to help!